Stay in touch
We'd love to keep in touch about news, events and how you can get involved. To hear from us, please sign up below.
We answer some common questions about the current COVID-19 vaccines and breast cancer treatments.
How does NICE decide whether to approve a new treatment?
The National Institute for Health and Care Excellence (NICE) will not recommend a drug called T-DM1 (Kadcyla) which is used to treat a type of secondary breast cancer for use on the NHS.
Rachel Rawson Clinical Nurse Specialist at Breast Cancer Care comments on research published in the journal Annals of Oncology.
The collaboration, called the international PALB2 Interest Group, have been investigating the impact of a faulty PALB2 gene on breast cancer risk. Their study, published in the New England Journal of Medicine, showed that women who carried rare mutations to the PALB2 gene were found to be more at risk of breast cancer than the general population. Importantly, the level of risk associated with these mutations was influenced by a woman’s family history of breast cancer.
What sets a scientist apart from the rest of the pack? I would suggest that timing plays a part, but I also have no doubt that you need to be innovative, diligent and dedicated to the cause in order to make the most out of the opportunities presented to you during your career.
Five UK hospitals are asking their patients with secondary breast cancer how they feel about the support and services available locally.
Many people tell us that they put on weight during and after treatment and they contact us for ideas on how to get back to their original weight.
Many people who call us on the Helpline think that having breast cancer automatically means chemotherapy. We discuss the treatment and its effects.
This summer get together with friends and family over a Strawberry Tea.